Effect of gastric inhibitory polypeptide on plasma levels of chylomicron triglycerides in dogs.
暂无分享,去创建一个
[1] R. Unger,et al. Release of pancreatic and gastric somatostatin-like immunoreactivity in response to the octapeptide of cholecystokinin, secretin gastric inhibitory polypeptide, and gastrin-17 in dogs. , 1980, Endocrinology.
[2] R. Eckel,et al. Gastric Inhibitory Polypeptide Enhanced Lipoprotein Lipase Activity in Cultured Preadipocytes , 1979, Diabetes.
[3] R. Unger,et al. Measurements of somatostatin-like immunoreactivity in plasma. , 1978, Clinica chimica acta; international journal of clinical chemistry.
[4] J. Brown,et al. Gastric Inhibitory Polypeptide: Its Physiologic Release and Insulinotropic Action in the Dog , 1975, Diabetes.
[5] E. Mazzaferri,et al. Gastric inhibitory polypeptide (GIP) stimulated by fat ingestion in man. , 1975, The Journal of clinical endocrinology and metabolism.
[6] J. Brown,et al. Stimulation of insulin secretion by gastric inhibitory polypeptide in man. , 1973, The Journal of clinical endocrinology and metabolism.
[7] R. Unger,et al. The effects of triglyceride absorption upon glucagon, insulin, and gut glucagon-like immunoreactivity. , 1973, The Journal of clinical investigation.
[8] S A BERSON,et al. Immunoassay of endogenous plasma insulin in man. , 1996, The Journal of clinical investigation.